Cleared Traditional

K801561 - GLYCOSYLATED HEMOGLOBIN KIT

K801561 is an FDA 510(k) clearance for GLYCOSYLATED HEMOGLOBIN KIT, manufactured by Amersham Corp.. The device is a Class 2 Hematology device with product code LCP cleared through the Traditional 510(k) pathway after a 35-day FDA review.

K801561 · Amersham Corp. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1980
Decision
35d
Days
Class 2
Risk

K801561 is an FDA 510(k) clearance for the GLYCOSYLATED HEMOGLOBIN KIT. Classified as Assay, Glycosylated Hemoglobin (product code LCP), Class II - Special Controls.

Submitted by Amersham Corp. (Mchenry, US). The FDA issued a Cleared decision on August 12, 1980 after a review of 35 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7470 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Amersham Corp. devices

FDA 510(k) Submission Details - K801561

510(k) Number K801561 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 08, 1980
Decision Date August 12, 1980
Days to Decision 35 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
78d faster than avg
Panel avg: 113d · This submission: 35d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LCP Device Classification - Class 2, Special Controls

Product Code LCP Assay, Glycosylated Hemoglobin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7470
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - LCP Assay, Glycosylated Hemoglobin

All 147
Devices cleared under the same product code (LCP) and FDA review panel - the closest regulatory comparables to K801561.
GLYCOHEMOGLOBIN IN WHOLE BLOOD
K802721 · Sigma Chemical Co. · Dec 1980
GLYCOSYLATED HEMOGLOBIN-SMC COLUMN
K802233 · Helena Laboratories · Oct 1980
HELENA GLYCOSYLATED HEMOGLOBIN QUIK METH
K800857 · Helena Laboratories · Sep 1980
LEECO GLYCO-HEMOGLOBIN DIAG. TEST KIT
K801289 · Leeco Diagnostics, Inc. · Jun 1980
FAST HEMOGLOBIN CONTROL-LYOPHILIZED
K800794 · Isolab, Inc. · Apr 1980
CORNING GLYCOSYLATED HEMOGLOBIN SET
K791777 · Corning Medical & Scientific · Nov 1979